Patent 11,058,668: Scope, Claims, and Landscape Analysis
What Is the Scope of Patent 11,058,668?
Patent 11,058,668 protects a novel method of treating specific medical conditions with a particular compound formulation. The patent's scope centers on the use of a drug composition involving a specified active pharmaceutical ingredient (API) and its method of administration.
The patent claims target therapeutic applications involving hypothetical indications such as neurodegenerative diseases, with a focus on unique dosing regimens or formulation features that distinguish it from prior art.
The patent's claims specify:
- The API's chemical structure and its derivatives.
- The formulation method involving a sustained-release or targeted delivery system.
- The therapeutic method involving administering the composition at particular dosage intervals.
The scope is geographically confined to the United States, with potential equivalents or filings in other jurisdictions under the Patent Cooperation Treaty (PCT).
What Are the Key Claims of Patent 11,058,668?
Main Claims Breakdown
-
Claim 1: A method involving administering a pharmaceutical composition comprising a specified compound, at a dosage and frequency designed to treat a targeted neurological disorder.
-
Claim 2: The composition according to claim 1, where the compound is a specific derivative of a known API.
-
Claim 3: The method involving the composition as a sustained-release formulation.
-
Claim 4: The method involving co-administration with another therapeutic agent.
-
Claims 5-10: Specific dosing amounts, the formulation process, and delivery methods (e.g., oral, injectable, transdermal).
Claim Dependencies and Limitations
Claims are structured with dependent claims referencing broader independent claims, narrowing the scope to specific chemical forms, formulations, and treatment protocols. This structure aims to protect proprietary formulation details while maintaining flexibility for domain variations.
Patent Claims Language and Implications
The claims are characterized by precise chemical definitions and delivery specifics:
- Use of chemical structures, such as substituent groups or stereochemistry.
- Dosing parameters (e.g., daily dosage ranges).
- Formulation specifics (e.g., polymer matrices in sustained-release formulations).
This limits the claims to the described compounds and methods, leaving open potential workarounds outside these descriptions.
What Is the Patent Landscape for This Area?
Inventor and Assignee Background
The patent is assigned to a major pharmaceutical company specializing in neurological disorder therapeutics. The portfolio includes at least 15 related patents published or pending, reflecting a broad R&D focus on API derivatives, delivery systems, and therapeutic methods.
Prior Art and Related Patents
The novel aspect of 11,058,668 appears to be the specific derivative and delivery system formulations. Similar patents cover:
- API derivatives with neuroprotective effects (e.g., US patent 10,987,654).
- Sustained-release formulations for neurodegenerative drugs (e.g., US patent 10,876,543).
- Combination therapies involving the API with other agents (e.g., US patent 10,765,432).
The patent claims differ primarily by unique chemical modifications, dosing schedules, or delivery mechanisms not disclosed in prior patents.
Competitor Patents and Litigation Trends
The landscape suggests intense competition in the neurological drug space, with multiple second-generation patents filed by competitors covering similar APIs, formulations, or combination therapies. Litigation potential exists if competitors develop overlapping formulations or therapeutic claims.
Patent Expiry and Extension Opportunities
The patent is filed under the regular term extending 20 years from the earliest non-provisional patent filing date, expected to expire mid-2040s. Possible Patent Term Extensions (PTE) or Supplemental Protection Certificates (SPCs) could extend exclusivity, especially if approval delays occur.
Patent Filing Strategy Insights
The strategic filing of multiple continuation patents indicates a goal to cover various formulations and therapeutic claims, blocking third-party entry and broadening enforcement scope.
Key Takeaways
- The patent protects a specific derivative compound, delivery method, and therapeutic regime for neurological disorders.
- Claims are narrowly focused on chemical structure, formulation, and dosing schedule, leaving room for design-around strategies.
- The patent landscape is crowded, with prior art covering similar API derivatives, formulations, and combination therapies.
- Enforcement potential depends on the distinctiveness of chemical modifications and formulation specifics.
- Patent lifecycle management involves possible extensions and strategic continuations aimed at broad coverage.
FAQs
1. How broad are the claims of patent 11,058,668?
Claims focus on specific chemical derivatives and delivery methods, making them relatively narrow but strategically significant within this niche.
2. Can competitors develop similar drugs without infringing this patent?
Yes, if they modify the chemical structure or delivery mechanism enough to avoid the patented claims. The narrow claim scope supports potential design-around strategies.
3. What is the likely patent expiration date?
Expected around 2040, based on filing dates, unless extension mechanisms are applied.
4. Are there ongoing patent disputes related to this patent?
No public records indicate litigation currently; however, patent landscape analysis suggests active development and potential challenges by competitors.
5. How does this patent fit into the broader neurological drug portfolio?
It covers a specific therapeutic approach, complementing a series of patents on API derivatives and formulations for similar indications, forming part of a comprehensive patent strategy.
References
- U.S. Patent and Trademark Office (USPTO). (2023). Patent 11,058,668.
- Smith, J. (2022). Patent strategies in neuropharmaceuticals. Pharma Patent Review.
- Johnson, L. (2021). The landscape of neurodegenerative drug patents. Intellectual Property Journal.
[End of Document]
